Your browser doesn't support javascript.
loading
METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics.
Jiang, Jiahui; Liu, Yunhe; Qin, Jiangjiang; Chen, Jianfeng; Wu, Jingjing; Pizzi, Melissa P; Lazcano, Rossana; Yamashita, Kohei; Xu, Zhiyuan; Pei, Guangsheng; Cho, Kyung Serk; Chu, Yanshuo; Sinjab, Ansam; Peng, Fuduan; Yan, Xinmiao; Han, Guangchun; Wang, Ruiping; Dai, Enyu; Dai, Yibo; Czerniak, Bogdan A; Futreal, Andrew; Maitra, Anirban; Lazar, Alexander; Kadara, Humam; Jazaeri, Amir A; Cheng, Xiangdong; Ajani, Jaffer; Gao, Jianjun; Hu, Jian; Wang, Linghua.
Afiliação
  • Jiang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu Y; School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Qin J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chen J; Department of Gastric Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
  • Wu J; Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Pizzi MP; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lazcano R; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yamashita K; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xu Z; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pei G; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cho KS; Department of Gastric Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
  • Chu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sinjab A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Peng F; School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Yan X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Han G; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dai E; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dai Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Czerniak BA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Maitra A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lazar A; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA.
  • Kadara H; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jazaeri AA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cheng X; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ajani J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gao J; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hu J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang L; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nat Commun ; 15(1): 7312, 2024 Aug 25.
Article em En | MEDLINE | ID: mdl-39181865
ABSTRACT
Recent advances in spatial transcriptomics (ST) techniques provide valuable insights into cellular interactions within the tumor microenvironment (TME). However, most analytical tools lack consideration of histological features and rely on matched single-cell RNA sequencing data, limiting their effectiveness in TME studies. To address this, we introduce the Morphology-Enhanced Spatial Transcriptome Analysis Integrator (METI), an end-to-end framework that maps cancer cells and TME components, stratifies cell types and states, and analyzes cell co-localization. By integrating spatial transcriptomics, cell morphology, and curated gene signatures, METI enhances our understanding of the molecular landscape and cellular interactions within the tissue. We evaluate the performance of METI on ST data generated from various tumor tissues, including gastric, lung, and bladder cancers, as well as premalignant tissues. We also conduct a quantitative comparison of METI with existing clustering and cell deconvolution tools, demonstrating METI's robust and consistent performance.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Perfilação da Expressão Gênica / Microambiente Tumoral / Transcriptoma / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Perfilação da Expressão Gênica / Microambiente Tumoral / Transcriptoma / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article